Literature DB >> 10147012

Prescription cost sharing: economic and health impacts, and implications for health policy.

R A Levy1.   

Abstract

Cost sharing for prescription pharmaceuticals--in the form of copayments, coinsurance, or deductibles--is now common in healthcare systems throughout the world. Although there are no studies that directly or convincingly measure the effects of prescription cost sharing on health status or treatment outcomes, cost sharing does appear to reduce utilisation of pharmaceuticals; however, more information is required concerning the relationship between cost sharing and prescription-filling behaviour. Additionally, outcomes studies are needed to define appropriate and inappropriate cost-sharing levels for particular groups of patients, based on income, disease, employment status, and other factors. Cost sharing for pharmaceuticals and other medical services is likely to increase in the near future. As a result, consumers will have a greater role in treatment decisions and will also become more interested in knowing the value of the medicines they are asked to purchase. They are therefore likely to demand pharmaceutical products that are more cost-effective and products that improve quality of life. The increased implementation of cost-sharing programmes necessitates the adoption of appropriate cost-sharing policies, which incorporate the following general principles: 1. Consumers must be provided with the information required to make informed decisions, including the value of the medication, its importance in the treatment plan, and the consequences of not having the prescription filled. 2. Aggressive or abusive cost-sharing features that deny access to optimal pharmaceutical therapy must be avoided. 3. Inappropriate cost sharing, either fixed level or percentage of the prescription cost, may affect disease control and ultimately health or functional status. 4. Cost sharing restricted to pharmaceuticals may encourage replacement of drug therapy with more expensive forms of treatment; therefore, cost sharing should apply to the full range of medical services to prevent service substitution.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 10147012     DOI: 10.2165/00019053-199202030-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  13 in total

Review 1.  Experience of state drug benefit programs.

Authors:  S B Soumerai; D Ross-Degnan
Journal:  Health Aff (Millwood)       Date:  1990       Impact factor: 6.301

2.  The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization.

Authors:  B L Harris; A Stergachis; L D Ried
Journal:  Med Care       Date:  1990-10       Impact factor: 2.983

3.  Impact of managed care on prescription drug use.

Authors:  J P Weiner; A Lyles; D M Steinwachs; K C Hall
Journal:  Health Aff (Millwood)       Date:  1991       Impact factor: 6.301

4.  Pharmacy benefits in health maintenance organizations.

Authors:  M Gold; M Joffe; T L Kennedy; A M Tucker
Journal:  Health Aff (Millwood)       Date:  1989       Impact factor: 6.301

5.  The differential impact of copayment on drug use in a Medicaid population.

Authors:  C E Reeder; A A Nelson
Journal:  Inquiry       Date:  1985       Impact factor: 1.730

6.  The demand for prescription drugs as a function of cost-sharing.

Authors:  A Leibowitz; W G Manning; J P Newhouse
Journal:  Soc Sci Med       Date:  1985       Impact factor: 4.634

7.  The effect of cost sharing on the use of antibiotics in ambulatory care: results from a population-based randomized controlled trial.

Authors:  B Foxman; R B Valdez; K N Lohr; G A Goldberg; J P Newhouse; R H Brook
Journal:  J Chronic Dis       Date:  1987

8.  Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.

Authors:  S B Soumerai; J Avorn; D Ross-Degnan; S Gortmaker
Journal:  N Engl J Med       Date:  1987-08-27       Impact factor: 91.245

9.  Some interim results from a controlled trial of cost sharing in health insurance.

Authors:  J P Newhouse; W G Manning; C N Morris; L L Orr; N Duan; E B Keeler; A Leibowitz; K H Marquis; M S Marquis; C E Phelps; R H Brook
Journal:  N Engl J Med       Date:  1981-12-17       Impact factor: 91.245

10.  Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes.

Authors:  S B Soumerai; D Ross-Degnan; J Avorn; T j McLaughlin; I Choodnovskiy
Journal:  N Engl J Med       Date:  1991-10-10       Impact factor: 91.245

View more
  13 in total

Review 1.  The effect of managed care on prescription drug costs and benefits.

Authors:  A Lyles; F B Palumbo
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

Review 2.  Pharmaceutical policies in Canada. Issues and challenges.

Authors:  D E Angus; H M Karpetz
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

3.  Overview of international pharmacy pricing.

Authors:  A I Wertheimer; S K Grumer
Journal:  Pharmacoeconomics       Date:  1992-12       Impact factor: 4.981

4.  Impact of consumer fees on drug utilisation.

Authors:  D G Smith; D M Kirking
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

5.  Economic impact of cost-containment strategies in third party programmes in the US (part I).

Authors:  C E Reeder; E W Lingle; R M Schulz; R P Mauch; B S Nightengale; C A Pedersen; M L Watrous; S E Zetzl
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

Review 6.  Costs, innovation and efficiency in anti-infective therapy.

Authors:  J L Bootman; R J Milne
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 7.  Pharmacy utilization and the Medicare Modernization Act.

Authors:  Vittorio Maio; Laura Pizzi; Adam R Roumm; Janice Clarke; Neil I Goldfarb; David B Nash; David Chess
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

8.  Clinical and economic evaluation of benzodiazepines: a value analysis.

Authors:  J S Lyons; D B Larson; J Hromco
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

9.  The role of insurance claims databases in drug therapy outcomes research.

Authors:  N J Lewis; J T Patwell; B A Briesacher
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

Review 10.  Economic cost of male erectile dysfunction using a decision analytic model: for a hypothetical managed-care plan of 100,000 members.

Authors:  H L Tan
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.